IP Library Granted Patent US 8,557,280
Granted Patent B2
US 8,557,280 · App. 13/768,897 · Granted Oct 15, 2013

Stable pharmaceutical composition and methods of using same

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,557,280
App. No.
13/768,897
Granted
Oct 15, 2013
Kind
B2
Abstract

The present invention relates to, inter alia, pharmaceutical compositions comprising a polyunsaturated fatty acid and to methods of using the same to treat or prevent cardiovascular-related diseases.

Claims (10)

1. A method of reducing triglycerides in a subject in need thereof who is on statin therapy comprising, administering to the subject 2500 mg to 5000 mg per day of ethyl eicosapentaenoate for a period effective to reduce triglycerides in the subject.

2. The method of claim 1 wherein the ethyl eicosapentaenoate is administered to the subject in dosage units each comprising about 500 mg to about 1.5 g of ethyl eicosapentaenoate.

3. The method of claim 2 wherein the dosage units are capsules.

4. The method of claim 1 wherein the ethyl eicosapentaenoate is administered to the subject in dosage units each comprising about 900 mg to about 1 g of ethyl eicosapentaenoate.

5. The method of claim 4 wherein the dosage units are capsules.

6. The method of claim 1 wherein the ethyl eicosapentaenoate is administered to the subject in dosage units each comprising about 1 g of ethyl eicosapentaenoate.

7. The method of claim 6 wherein the dosage units are capsules.

8. The method of claim 1 wherein the ethyl eicosapentaenoate is present in a pharmaceutical composition comprising other fatty acids or esters thereof and said ethyl eicosapentaenoate comprises at least about 90%, by weight, of the fatty acids present in the composition.

9. The method of claim 1 wherein the period is effective to reduce LDL-C in the subject.

10. The method of claim 1 wherein the subject has mixed dyslipidemia.

Assignments (3)
RELEASE OF SECURITY INTEREST Recorded Nov 19, 2020
From: CPPIB CREDIT EUROPE S.À R.L.
To: AMARIN PHARMACEUTICALS IRELAND LIMITED
Reel/Frame 054484/0552 →
SECURITY INTEREST Recorded Dec 21, 2017
From: AMARIN PHARMACEUTICALS IRELAND LIMITED
To: CPPIB CREDIT EUROPE S.À R.L.
Reel/Frame 044938/0257 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 5, 2013
From: MANKU, MEHAR; OSTERLOH, IAN; WICKER, PIERRE; BRAECKMAN, RENE; SONI, PARESH
To: AMARIN PHARMACEUTICALS IRELAND LIMITED
Reel/Frame 030943/0354 →